Adalimumab vs tocilizumab for severe Behçet eye inflammation
Treatments studied
Part of Eyes & vision, Immune system & allergy clinical trials.
This study compares two medicines—adalimumab and tocilizumab—to see which works better and is safer for severe “uveitis” in people with Behçet’s disease. It’s meant for adults whose eye inflammation threatens their sight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign informed consent
- Have Behçet’s disease (or a history of mouth sores called aphthosis)
- Have non-infectious eye inflammation (intermediate/posterior/pan-uveitis) in at least one eye, confirmed by eye criteria
- Have sight-threatening disease, such as a significant drop in vision and/or retinal inflammation
- Have a chest X-ray or CT within 12 weeks showing no active tuberculosis, infection, or cancer
- If you can become pregnant: have a negative pregnancy test and agree to strong birth control during treatment and for a set time after stopping
- Agree to avoid certain infections/vaccines and meet blood/liver/kidney safety lab thresholds
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adalimumab (an immune medicine) added to a medium-dose steroid improves eye inflammation from refractory Behçet’s disease that keeps coming back. It also checks safety to see if the benefits outweigh risks.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
This trial tests a combination of two medications (adalimumab and mycophenolate mofetil) to reduce eye inflammation in people with uveitis that requires steroids. It aims to help patients use less steroid medication while keeping their uveitis under control.
This study tests if ustekinumab or apremilast can help control Behçet's disease symptoms like mouth and genital ulcers, skin sores, and joint pain. It may be an option if standard treatments haven't worked well.
Hear when a new Behcet's Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.